Results 31 to 40 of about 27,707 (119)

Allosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptor. [PDF]

PLoS ONE, 2012
Glucagon-like peptide-1 (GLP-1) released from intestinal L cells in response to nutrients has many physiological effects but particularly enhances glucose-dependent insulin release through the GLP-1 receptor (GLP-1R).
Naichang Li, Jing Lu, Gary B Willars
doaj   +1 more source

Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists

Molecular Metabolism, 2021
Objective: We assessed the spatiotemporal GLP-1 and GIP receptor signaling, trafficking, and recycling dynamics of GIPR mono-agonists, GLP-1R mono-agonists including semaglutide, and GLP-1/GIP dual-agonists MAR709 and tirzepatide.
Aaron Novikoff, Shannon L. O'Brien, Miriam Bernecker, Gerald Grandl, Maximilian Kleinert, Patrick J. Knerr, Kerstin Stemmer, Martin Klingenspor, Anja Zeigerer, Richard DiMarchi, Matthias H. Tschöp, Brian Finan, Davide Calebiro, Timo D. Müller   +13 more
doaj   +1 more source

Differential Cardiometabolic Effects of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Early-Onset Type 2 Diabetes: A Randomized Controlled Trial

Link Medical Journal of Health and Community Research
Introduction: Early-onset type 2 diabetes mellitus is characterized by higher exposure to cardiometabolic risk throughout life and increased risk of cardiovascular morbidity.
Marriam Abid, Samia Gull Akhtar, Tabinda Razzaq, Zia Ullah, Shah Abdul Latif, Hafiz Muhammad Qasim, Muhammad Abbas Sadiq   +6 more
doaj   +1 more source

Challenging the Dogma: Reversal of End-Stage Liver Fibrosis with Tirzepatide in MASH Cirrhosis

Transplantology
Background/Objectives: The growing prevalence of metabolic-associated steatotic liver disease (MASLD)/metabolic-associated steatohepatitis (MASH) is forecasted to be over 55% by 2040, representing a significant driver of cirrhosis and highlighting demand
Thuy-Duyen Nguyen, Dora Lam-Himlin, Blanca Lizaola-Mayo, David Chascsa   +3 more
doaj   +1 more source

Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity

Obesity Facts, 2020
Objective: Hypothalamic obesity (HO) in children after treatment for a tumor in the suprasellar region has severe implications. Previous studies have shown various effects of glucagon-like peptide-1 (GLP-1) receptor agonist in acquired HO, but in adults ...
Jiska van Schaik, Dominique G.A. Begijn, Laura van Iersel, Yvonne Vergeer, Eelco W. Hoving, Babette Peeters, Hanneke M. van Santen   +6 more
doaj   +1 more source

Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study

The Lancet. Healthy Longevity
Summary: Background: GLP-1 receptor agonists and SGLT2 inhibitors are increasingly being used in people with type 2 diabetes on the basis of findings from randomised clinical trials; however, little is known of whether clinical outcomes are affected by ...
ProfPhD Fei-Yuan Hsiao, Elise Chia-Hui Tan, PhD, Lin-Chieh Meng, MS, Yi-Chin Lin, PharmD MS, Ho-Min Chen, MS, Shang-Ting Guan, PharmD, ProfMD PhD Der-Cherng Tarng, PharmD, ProfMD PhD Chih-Yuan Wang, PharmD, Prof Liang-Kung Chen, PharmD   +8 more
doaj   +1 more source

Prevention of biliary diseases associated with GLP-1 receptor agonist therapy

Лечащий Врач
Background. In recent years, glucagon-like peptide-1 receptor agonists (GLP-1a) have emerged as pivotal therapeutic agents in the management of metabolic disorders, particularly type 2 diabetes mellitus and obesity.
Elena A. Ljaljukova
doaj   +1 more source

GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review

EClinicalMedicine
Summary: Despite the availability of a wide range of antihypertensive agents, a significant proportion of individuals with resistant hypertension (RHTN) struggle to achieve blood pressure (BP) control.
Candace Jarade, Tetiana Zolotarova, Areesha Moiz, Mark J. Eisenberg   +3 more
doaj   +1 more source

Retatrutide-Induced Intractable Diarrhea

Annals of Internal Medicine: Clinical Cases
Gastrointestinal symptoms accompanying the use of glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide receptor-GLP-1 receptor co-agonists have been extensively catalogued.
Opeyemi Komolafe
doaj   +1 more source

Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analogues

Molecular Metabolism
Objectives: Unimolecular triagonists drive substantial weight loss in patients with obesity by engaging the glucagon-like peptide 1 receptor (GLP-1R) and glucose dependent insulinotropic polypeptide receptor (GIPR) to reduce food intake (FI) and the ...
Jonathan D. Douros, Megan Capozzi, Aaron Novikoff, Jacek Mokrosinski, Barent DuBois, Joseph Stock, Rebecca Rohlfs, Mikayla Anderson, Dominika J. Jedrzejcyk, Svend Poulsen, Erik Oude Blenke, Tomas Dago, Kasper Huus, Peder L. Nørby, Sune Kobberup, Marita Rivir, Joyce Sorrell, Stephanie A. Mowery, Daniel J. Drucker, David A. D'Alessio, Jonathan E. Campbell, Timo D. Müller, Diego Perez-Tilve, Brian Finan, Patrick J. Knerr   +24 more
doaj   +1 more source